Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 508 Results

Page 50 of 51« First «...10 20 30...47 48 495051 »

January 31, 2012

DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiers

December 6, 2011

DBV Technologies introduces its new Chief Financial Officer

September 21, 2011

DBV Technologies moves to Bagneux

June 8, 2011

DBV Technologies VIASKIN^® technology has been chosen to feature on the cover of the European Journal of Allergy and Clinical Immunology June 2011 issue in its timeline “100 years allergen specific immunotherapy.”

January 18, 2011

DBV Technologies elects George Horner as non executive Chairman

January 8, 2011

DBV Technologies is very proud to have been chosen to feature on the cover of the Journal of Allergy and Clinical Immunology January 2011 issue

January 5, 2011

DBV Technologies closes $25.5 (€19,4) million Series ‘C’ financing round

September 23, 2010

DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN®

September 1, 2010

VIASKIN^® PEANUT Selected for U.S. Consortium of Food Allergy Research’s Peanut Allergy Desensitization Trial

July 6, 2010

DBV Technologies Receives IND Clearance From FDA to Begin Clinical Trial in Peanut Allergy

Page 50 of 51« First «...10 20 30...47 48 495051 »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top